{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:28:56Z","timestamp":1781854136809,"version":"3.54.5"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Graft-versus-host disease (GVHD) remains a potentially fatal complication of allogeneic hematopoietic stem cell transplantation (alloHCT). Gastrointestinal involvement, whether in acute or chronic GVHD, is associated with a poorer prognosis and poses significant diagnostic and therapeutic challenges. Numerous studies have attempted to identify markers that could facilitate the diagnosis and predict the course of GVHD. Among them, REG3\u03b1 and ST2 currently show the greatest promise; however, comprehensive validation remains lacking. Although several new drugs have been approved for GVHD treatment in recent years and some modifications to GVHD prophylaxis have been adopted into clinical practice, further research are needed to validate biomarkers and explore new therapeutic targets, particularly in gastrointestinal GVHD. The review aims to summarize current research on GVHD biomarkers and emerging treatment targets, with a particular focus on gastrointestinal tract disease.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1645503","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:11:58Z","timestamp":1758514318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Katarzyna","family":"Wiejak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Przyby\u0142kowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Tomaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-44080-9","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Sureda","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.126","article-title":"Acute graft-versus-host disease of the gut: considerations for the gastroenterologist","volume":"14","author":"Naymagon","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the Mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological Malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00079","article-title":"Pathophysiology of GvHD and other HSCT-related major complications","volume":"8","author":"Ghimire","year":"2017","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90592","article-title":"Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis","volume":"127","author":"Ferrara","year":"2017","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375006","article-title":"Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease","volume":"118","author":"Ferrara","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm1720","article-title":"Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens","volume":"14","author":"Zheng","year":"2008","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99261","article-title":"Survival signal REG3\u03b1 prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease","volume":"128","author":"Zhao","year":"2018","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387357","article-title":"Plasma biomarkers of lower gastrointestinal and liver acute GVHD","volume":"119","author":"Harris","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008480","article-title":"Reg3alpha concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use","volume":"7","author":"Weber","year":"2023","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005420","article-title":"Regenerating islet-derived protein 3-alpha is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease","volume":"6","author":"DePriest","year":"2022","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606830","article-title":"The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD","volume":"125","author":"Reichenbach","year":"2015","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.009","article-title":"Pretransplantation plasma ST2 level as a prognostic biomarker of 1-year nonrelapse mortality in allogeneic hematopoietic cell transplantation","volume":"29","author":"Gjaerde","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2014-06-584789","article-title":"High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation","volume":"125","author":"Ponce","year":"2015","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2019.2019.0139","article-title":"Predictive values of early suppression of tumorigenicity 2 for acute GVHD and transplant-related complications after allogeneic stem cell transplantation: prospective observational study","volume":"37","author":"Matsumura","year":"2020","journal-title":"Turk J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.06.011","article-title":"A novel soluble form of Tim-3 associated with severe graft-versus-host disease","volume":"19","author":"Hansen","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387977","article-title":"Contrasting acute graft-versus-host disease effects of Tim-3\/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells","volume":"120","author":"Veenstra","year":"2012","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1738097","article-title":"Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients","volume":"25","author":"Yegin","year":"2020","journal-title":"Hematology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.002","article-title":"Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients","volume":"14","author":"Kitko","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8924(00)89088-1","article-title":"Two tumour necrosis factor receptors: structure and function","volume":"5","author":"Vandenabeele","year":"1995","journal-title":"Trends Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.360","article-title":"Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning","volume":"45","author":"Willems","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-138867","article-title":"Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival","volume":"112","author":"Choi","year":"2008","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.016","article-title":"Easix score correlates with endothelial dysfunction biomarkers and predicts risk of acute graft-versus-host disease after allogeneic transplantation","volume":"30","author":"Pedraza","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.121","article-title":"Endothelial damage is aggravated in acute GvHD and could predict its development","volume":"52","author":"Mir","year":"2017","journal-title":"Bone Marrow Transpl"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000396","article-title":"IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling","volume":"134","author":"Wilkinson","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02319","article-title":"Interleukin-6 as biomarker for acute GvHD and survival after allogeneic transplant with post-transplant cyclophosphamide","volume":"10","author":"Greco","year":"2019","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005957","article-title":"Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans","volume":"136","author":"Norona","year":"2020","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00039.2011","article-title":"The \u201ccryptic\u201d mechanism of action of glucagon-like peptide-2","volume":"301","author":"Rowland","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.2527\/jas.2014-8577","article-title":"COMPARATIVE GUT PHYSIOLOGY SYMPOSIUM: Comparative physiology of glucagon-like peptide-2: Implications and applications for production and health of ruminants","volume":"93","author":"Connor","year":"2015","journal-title":"J Anim Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31068","article-title":"Biological actions and therapeutic potential of the glucagon-like peptides","volume":"122","author":"Drucker","year":"2002","journal-title":"Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18778","article-title":"Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2","volume":"201","author":"Zeiser","year":"2023","journal-title":"Br J Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017343","article-title":"Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302\/0802","volume":"2","author":"Holtan","year":"2018","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0170-z","article-title":"Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid","volume":"32","author":"Amin","year":"2019","journal-title":"Mod Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-669846","article-title":"Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors","volume":"128","author":"Holtan","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.05.021","article-title":"Phase II, open-label clinical trial of urinary-derived human chorionic gonadotropin\/epidermal growth factor for life-threatening acute graft-versus-host disease","volume":"29","author":"Holtan","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701163","article-title":"Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation","volume":"21","author":"Foley","year":"1998","journal-title":"Bone Marrow Transpl"},{"key":"B40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/15258160050079506","article-title":"Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"9","author":"Mathias","year":"2000","journal-title":"J Hematother Stem Cell Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.106774","article-title":"Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"106","author":"Nakamura","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"B42","article-title":"Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease","volume":"17","author":"Miyamoto","year":"1996","journal-title":"Bone Marrow Transpl"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709058342","article-title":"Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease","volume":"28","author":"Kobayashi","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02168-0","article-title":"Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study","volume":"59","author":"McCarthy","year":"2024","journal-title":"Bone Marrow Transpl"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.41","article-title":"Monitoring of TNFR1, IL-2Ralpha, HGF, CCL8, IL-8 and IL-12p70 following HSCT and their role as GVHD biomarkers in paediatric patients","volume":"48","author":"Berger","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00035-0","article-title":"A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study","volume":"2","author":"Levine","year":"2015","journal-title":"Lancet Haematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"124015","DOI":"10.1172\/jci.insight.124015","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"3","author":"Hartwell","year":"2018","journal-title":"JCI Insight"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.04.029","article-title":"Predictive value of clinical findings and plasma biomarkers after fourteen days of prednisone treatment for acute graft-versus-host disease","volume":"23","author":"McDonald","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03158","article-title":"Preliminary results of a combined score based on sIL2-ralpha and TIM-3 levels assayed early after hematopoietic transplantation","volume":"10","author":"Leotta","year":"2019","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011049","article-title":"Amphiregulin, ST2, and REG3alpha biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD","volume":"8","author":"Etra","year":"2024","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007477","article-title":"Prospective external validation of biomarkers to predict acute graft-versus-host disease severity","volume":"6","author":"Robin","year":"2022","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.26","article-title":"Prognostic plasma biomarkers of early complications and graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"1","author":"Balakrishnan","year":"2020","journal-title":"EJHaem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.01.080","article-title":"Use of teduglutide in the management of gastrointestinal graft-versus-host disease in children and young adults","volume":"30","author":"Ramos","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.119.262238","article-title":"Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome","volume":"373","author":"Hargrove","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","article-title":"ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease","volume":"7","author":"Zhang","year":"2015","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.3c00122","article-title":"Prophylactic mitigation of acute graft versus host disease by novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-based stimulation-2 (ST2) inhibitors","volume":"6","author":"Yuan","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.001","article-title":"Tocilizumab for the treatment of steroid refractory graft-versus-host disease","volume":"17","author":"Drobyski","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1045896","article-title":"Tocilizumab for steroid refractory acute graft-versus-host disease","volume":"57","author":"Roddy","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009050","article-title":"A phase 3 double-blind study of the addition of tocilizumab vs. placebo to cyclosporin\/methotrexate GVHD prophylaxis","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03968-w","article-title":"IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"99","author":"Kattner","year":"2020","journal-title":"Ann Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0236-z","article-title":"Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract","volume":"54","author":"Ganetsky","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015111","article-title":"A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","volume":"141","author":"Ponce","year":"2023","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.03.013","article-title":"TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes","volume":"18","author":"Choi","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-112987","article-title":"Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease","volume":"111","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.023","article-title":"Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"20","author":"Gatza","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.29.5.630","article-title":"Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Park","year":"2014","journal-title":"Korean J Intern Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0187184","DOI":"10.1371\/journal.pone.0187184","article-title":"Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience","volume":"12","author":"De Jong","year":"2017","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.039","article-title":"Combination therapy with inolimomab and etanercept for severe steroid-refractory acute graft-versus-host disease","volume":"22","author":"van Groningen","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.003","article-title":"A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease","volume":"15","author":"Couriel","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03016-4","article-title":"Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.12.011","article-title":"Vedolizumab for steroid refractory lower gastrointestinal tract graft-versus-host disease","volume":"27","author":"Mehta","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0364-5","article-title":"Anti-alpha4beta7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease","volume":"54","author":"Danylesko","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.11.013","article-title":"Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: A retrospective record review","volume":"25","author":"Floisand","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"B77","doi-asserted-by":"publisher","first-page":"20406207241276982","DOI":"10.1177\/20406207241276982","article-title":"Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease","volume":"15","author":"Zu","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12185-025-03955-9","article-title":"Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study","volume":"122","author":"Goto","year":"2025","journal-title":"Int J Hematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815746","article-title":"alpha(1)-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease","volume":"131","author":"Magenau","year":"2018","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003336","article-title":"Biomarker-guided preemption of steroid-refractory graft-versus-host disease with alpha-1-antitrypsin","volume":"4","author":"Gergoudis","year":"2020","journal-title":"Blood Adv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.05.011","article-title":"Response of steroid-refractory acute GVHD to alpha1-antitrypsin","volume":"22","author":"Marcondes","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.05.014","article-title":"Human-derived alpha1-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease","volume":"26","author":"Giannoni","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25839","article-title":"Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study","volume":"95","author":"Liu","year":"2020","journal-title":"Am J Hematol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1277307","DOI":"10.1080\/2162402X.2016.1277307","article-title":"Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study","volume":"6","author":"Tan","year":"2017","journal-title":"Oncoimmunology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05631.x","article-title":"Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease","volume":"130","author":"Schmidt-Hieber","year":"2005","journal-title":"Br J Haematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12691","article-title":"Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody","volume":"97","author":"Chakupurakal","year":"2016","journal-title":"Eur J Haematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.03.044","article-title":"Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched\/haploidentical hematopoietic stem cell transplantation","volume":"43","author":"Wang","year":"2011","journal-title":"Transplant Proc"},{"key":"B88","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/sj.bmt.1703737","article-title":"Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"30","author":"Massenkeil","year":"2002","journal-title":"Bone Marrow Transpl"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705306","article-title":"Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist","volume":"37","author":"Funke","year":"2006","journal-title":"Bone Marrow Transpl"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/cancers16233912","article-title":"Combined cytokine blockade therapy (CCBT) using basiliximab and infliximab for treatment of steroid-refractory graft-versus-host disease (SR-GvHD)","volume":"16","author":"Pourhassan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.247","article-title":"The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD","volume":"51","author":"Nadeau","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05361-9","article-title":"Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study","volume":"102","author":"Liu","year":"2023","journal-title":"Ann Hematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408211","article-title":"Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27424","article-title":"An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent\/steroid-resistant chronic GVHD","volume":"99","author":"Inamoto","year":"2024","journal-title":"Am J Hematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2409876","article-title":"Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies","volume":"66","author":"Caputo","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02554-w","article-title":"Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"60","author":"Michonneau","year":"2025","journal-title":"Bone Marrow Transpl"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019107","article-title":"Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"141","author":"Koshy","year":"2023","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"131","author":"Nahas","year":"2018","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645503\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:11:59Z","timestamp":1758514319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645503\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":101,"alternative-id":["10.3389\/fimmu.2025.1645503"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1645503","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1645503"}}